Restenosis Stent Study (REST) confirms lower reintervention for stents
This article was originally published in Clinica
Executive Summary
Bleeding complications are twice as common in heparinised stent patients but PTCA still requires more reinterventions, show early data from the multinational Restenosis Stent study, REST. Dr Raimund Erbel of the University of Essen in Germany said interim analysis of the first 200 patients to complete six months follow up in the 18-centre study showed an average difference of 0.24 mm in minimum luminal diameter (MLD) in the favour of stent patients. However, 12.2% of the stent patients suffered from bleeding complications compared with only 5.9% of those who underwent PTCA. As a result the average hospital stay for those receiving stent treatment was 5.8 days while PTCA patients left after 3.2 days.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.